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ABSTRACT 
 
Diabesity, the Obesity-Diabetes Epidemic, is one of the major global health problems. Complications associated 
with it resulted in serious complications and need urgent attention for new therapeutic approaches. In recent 
years, evidence supporting role of Matrix metalloproteinases and their inhibitors in development of diabesity 
associated complications are increased. Due to their role in diabesity associated complications they may be 
potential therapeutic targets. 
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Introduction 
Diabesity, the term denotes diabetes in the 
context of obesity, is one of the foremost epidemic 
problems. [1] In the recent time prevalence of obesity 
and type two diabetes had a rapid rise worldwide. 
They are mainly contributed to sedentary lifestyle and 
diet apart from genetic susceptibility [2, 3]. Both of 
these conditions diabetes and obesity leads to an 
increase risk of developing complications and 
comorbid disease conditions like cardiovascular 
disease, hypertension and stroke, which can 
complicate disease management. Evidence from the 
recent studies associated matrix metalloproteinases 
(MMPs) with the development and advancement of 
diabetic microvascular complications [4]. In 
cardiomyopathy associated to diabes, MMPs play 
important role in breakdown of collagen and elastin, 
remodelling of myocardiam as well as the coronary 
plaque vulnerability. Further altered MMPs expression 
leads to extracellular matrix deposition resulted in 
glomerular hypertrophy that ultimately lead to renal 
complications [5]. Altered levels of MMPs causes 
impaired angiogenesis thus the development of 
diabetic peripheral arterial disease [6]. Studies reported 
role of MMPs in cerebral circulation, stroke volume in 
diabetes and imparement in diabetic wound healing [7-
9]. Table 1 showed activity of various MMPs in 
obesity and diabetes. 
 
MMPs in obesity  
For the role of MMPs pattern in obesity 
conflicting observations are reported. In experimental 
animal models increased level of mRNA levels of 
MMP-2, MMP-3, and other MMPs have been reported 
in adipose tissue [10]. It has been hypothesized that 
MMPs may be associated with adipose tissue 
remodeling and differentiation of pre-adipocytes [11-
13]. Neutrophils and endothelial cells produced MMP-
8 is a collagenase that is involved in collagen 
breakdown resulted in increased vulnerability of 
atherosclerotic plaques [14]. In another study 
significantly increased levels of MMP-9 were observed 
obese hypertensive children compared to 
normotensive; in the same study correlation of MMP-
9 with BMI, systolic blood pressure and fasting plasma 
insulin was also established [15]. Furthermore higher 
levels of plasma MMP-9 and lower levels of MMP-2 in 
obese women compared to lean ones are also reported 
[16]. However some authors reported increased levels 
of MMP-2 and MMP-9 in obese subjects and 
suggested abnormal extracellular matrix metabolism in 
these subjects [17]. 
 
Table 1. MMPs and TIMPs expression in obesity and type 2 diabetes 
mellitus 
 
MMP type Obesity 
 
Diabetes mellitus 
 
MMP-2   
MMP-3  
MMP-7  No data 
MMP-8  No data 
MMP-9   
MMP-10 No data No data 

: Increased, : Decreased, : Some studies reported increase 
while other reported decrease 
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MMPs in diabetes  
Role of MMPs is widely studied by many researchers 
and although some authors have reported increase in 
MMPs levels in diabetes some have not observe any 
difference in plasma concentrations of MMP-2 and 
MMP-9 [18]. In diabetic cultured endothelial cells and 
monocyte derived macrophages, under elevated 
glucose concentration conditions, increased expression 
of MMP-1, MMP-2, and MMP-9 is reported [19]. 
Furthermore in similar conditions decrease in MMP-3, 
however no significant change on TIMP-1 expression 
was observed [19]. Some studies reported that MMP 
activity of mesangial cell controls ECM degradation 
that leads to pathogenesis of diabetic nephropathy [20, 
21]. Different mechanisms are proposed  by which 
hyperglycemia  regulate MMP gene expression 
including protein kinase C (PKC) agonists, cytokines, 
TGF-b, and nuclear factor-κB (NF-κB). It is not clear 
how hyperglycemia alter MMP expression. For 
example, glycation of the ECM decreases MT1-MMP 
expression in diabetics the but at the same time 
increases MMP-2, TIMP-1, and TIMP-2 expression 
[22]. Increased level of MMPs in heart failure patients 
and further increase in level with progression of heart 
failure have been reported [23]. In another study 
significant increase in MMPs levels within hours of the 
precipitation of myocardial infarction have been 
reported that was followed by local activation of 
cytokines and infiltration of inflammatory cells [24]. 
Enhanced MMP-2 activity by high glucose 
concentrations is observed in human retinal pericytes 
and decreased by modification with thiamine that 
controls AGE formation, ROS production, and polyol 
pathway [25]. MMP-2 and MMP-9, TIMP-1 and 
TIMP-2 were significantly higher in type 2 diabetes 
patent compared to controls, especially in those with 
acute coronary syndrome [26]. 
 
Concluding remarks  
MMPs play important role in diabesity and 
leads to precipitation of various complications and 
comorbidities associated with diabetes and obesity. 
Various MMPs based on their level can be targeted for 
treatment of diabesity associated complications. 
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